Related Experiment Video
Updated: Aug 13, 2026

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
Benzydamine attenuates microglia-mediated neuroinflammation and ischemic brain injury by targeting cathepsin s
Yuxin Zhang1, Lixuan Yang2, Yonghui Gan1
1Department of Neurology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210008, China; Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
Abstract:
Microglia, the primary immune cells of the central nervous system, play a crucial role in the neuroinflammatory processes following ischemic stroke. Targeting neuroinflammation is a promising strategy to enhance the outcomes of ischemic stroke. Benzydamine (BA), a well-known non-steroidal anti-inflammatory drug, has demonstrated potential in inhibiting pro-inflammatory cytokines across various disease models. However, the potential role of BA in microglial activation and post-stroke neuroinflammation remains unclear. Our study reveals that BA effectively suppresses the lipopolysaccharide (LPS)-stimulated pro-inflammatory responses of primary microglia, with high-dose BA (10 μM) suppressing LPS-induced inflammatory markers by up to 59.1 % in the mRNA levels of IL-1β. Furthermore, BA mitigated ischemic brain injury in experimental stroke mice. BA treatment also significantly attenuated neuroinflammatory responses and attenuates ischemic brain injury in experimental stroke mice. Further investigation revealed that BA reduces the release of the LPS-stimulated pro-inflammatory factors and activation of primary microglia by directly binding to and inhibiting the activity of cathepsin S (CTSS). In conclusion, our study identifies BA as a promising CTSS inhibitor with potential to suppress neuroinflammation following ischemic stroke. Our findings provide a theoretical basis for developing new neuroprotective strategies.
Insights
Benzydamine (BA) reduces neuroinflammation and brain injury after ischemic stroke by inhibiting microglia activation. This non-steroidal anti-inflammatory drug targets cathepsin S, offering a new neuroprotective strategy.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Microglia are key immune cells in the central nervous system, driving neuroinflammation in ischemic stroke.
- Targeting neuroinflammation is a critical strategy for improving stroke outcomes.
- Benzydamine (BA), an NSAID, shows anti-inflammatory potential but its role in stroke-related microglial activation is unknown.
Purpose of the Study:
- To investigate the effect of Benzydamine (BA) on microglial activation and neuroinflammation in ischemic stroke.
- To determine if BA can mitigate brain injury in experimental stroke models.
- To elucidate the molecular mechanism underlying BA's action in neuroinflammation.
Main Methods:
- Primary microglia were stimulated with lipopolysaccharide (LPS) to assess inflammatory responses.
- Benzydamine (BA) treatment effects on inflammatory markers (e.g., IL-1β mRNA) were quantified.
- Experimental stroke mice were used to evaluate BA's efficacy in mitigating brain injury and neuroinflammation.
- The interaction of BA with cathepsin S (CTSS) was investigated.
Main Results:
- BA significantly suppressed LPS-induced pro-inflammatory responses in primary microglia, reducing IL-1β mRNA levels by up to 59.1% at 10 μM.
- BA treatment attenuated ischemic brain injury and neuroinflammation in experimental stroke mice.
- BA was found to directly inhibit cathepsin S (CTSS) activity, reducing pro-inflammatory factor release and microglial activation.
Conclusions:
- Benzydamine (BA) effectively suppresses microglial activation and neuroinflammation post-ischemic stroke.
- BA acts as a cathepsin S (CTSS) inhibitor, offering a novel mechanism for neuroprotection.
- BA presents a promising therapeutic candidate for managing ischemic stroke and associated neuroinflammation.
Related Concept Videos
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
CNS Depressants: Alcohol and Nicotine
Vascular Spasm

